NO20065814L - Thiendopyridinon forbindelser og fremgangsmater for behandling - Google Patents
Thiendopyridinon forbindelser og fremgangsmater for behandlingInfo
- Publication number
- NO20065814L NO20065814L NO20065814A NO20065814A NO20065814L NO 20065814 L NO20065814 L NO 20065814L NO 20065814 A NO20065814 A NO 20065814A NO 20065814 A NO20065814 A NO 20065814A NO 20065814 L NO20065814 L NO 20065814L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- methods
- vomiting
- ischemic stroke
- depression
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 208000032382 Ischaemic stroke Diseases 0.000 abstract 2
- 206010047700 Vomiting Diseases 0.000 abstract 2
- 230000008673 vomiting Effects 0.000 abstract 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 abstract 1
- 206010038678 Respiratory depression Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000006549 dyspepsia Diseases 0.000 abstract 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 239000004031 partial agonist Substances 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57185204P | 2004-05-17 | 2004-05-17 | |
| US10/955,434 US7488736B2 (en) | 2004-05-17 | 2004-09-30 | Thienopyridinone compounds and methods of treatment |
| PCT/US2005/017121 WO2005121151A2 (en) | 2004-05-17 | 2005-05-16 | Thienopyridinone compounds and methods of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20065814L true NO20065814L (no) | 2007-02-12 |
Family
ID=35310219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20065814A NO20065814L (no) | 2004-05-17 | 2006-12-15 | Thiendopyridinon forbindelser og fremgangsmater for behandling |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7488736B2 (https=) |
| EP (1) | EP1746994A4 (https=) |
| JP (1) | JP4897683B2 (https=) |
| KR (1) | KR101216296B1 (https=) |
| AU (1) | AU2005252632B2 (https=) |
| BR (1) | BRPI0510022A (https=) |
| CA (1) | CA2567268C (https=) |
| IL (1) | IL178996A0 (https=) |
| MA (1) | MA28582B1 (https=) |
| NO (1) | NO20065814L (https=) |
| RU (1) | RU2006144867A (https=) |
| WO (1) | WO2005121151A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612078B2 (en) * | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US20050222175A1 (en) * | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US7488736B2 (en) | 2004-05-17 | 2009-02-10 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| US7576211B2 (en) * | 2004-09-30 | 2009-08-18 | Epix Delaware, Inc. | Synthesis of thienopyridinone compounds and related intermediates |
| US7407966B2 (en) * | 2004-10-07 | 2008-08-05 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| US7598265B2 (en) * | 2004-09-30 | 2009-10-06 | Epix Delaware, Inc. | Compositions and methods for treating CNS disorders |
| WO2006081332A1 (en) * | 2005-01-25 | 2006-08-03 | Epix Delaware, Inc. | Substituted arylamine compounds and their use as 5-ht6 modulators |
| CN101384367B (zh) * | 2006-02-14 | 2012-05-30 | 埃克森美孚化学专利公司 | 一种制造mcm-22族分子筛的方法 |
| US8114894B2 (en) * | 2008-12-03 | 2012-02-14 | Nanotherapeutics, Inc. | Bicyclic compounds and methods of making and using same |
| US8557994B2 (en) * | 2009-07-27 | 2013-10-15 | Daljit Singh Dhanoa | Deuterium-enriched pyridinonecarboxamides and derivatives |
| US9453027B2 (en) | 2009-07-27 | 2016-09-27 | Daljit Singh Dhanoa | Deuterium-enriched pyridinonecarboxamides and derivatives |
| CA2813711A1 (en) | 2010-10-14 | 2012-04-19 | Immunahr Ab | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators. |
| WO2013009830A1 (en) * | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013009812A1 (en) * | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc | Methods of treatment |
| WO2013009810A1 (en) * | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| WO2013009827A1 (en) * | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| LT4004002T (lt) | 2019-07-22 | 2024-10-25 | Lupin Limited | Makrocikliniai junginiai kaip sting agonistai ir jų naudojimo būdai bei metodai |
| CN114569566A (zh) * | 2020-12-02 | 2022-06-03 | 四川科瑞德制药股份有限公司 | 一种盐酸米那普仑制剂的制备方法 |
| IL314038A (en) | 2022-01-11 | 2024-09-01 | Suven Life Sciences Ltd | Pyrrolo[1,2-b]-2-pyridazinone compounds as 5-HT4 receptor agonists |
| US11725016B1 (en) * | 2022-06-02 | 2023-08-15 | Nanopharmaceutics, Inc | Compositions and methods for oral delivery of crystalline PRX-3140 potassium salt |
| EP4719356A1 (en) * | 2023-06-05 | 2026-04-08 | Nanopharmaceutics, Inc. | Compositions and methods for oral delivery of sustained release crystalline prx-3140 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3069412A (en) * | 1958-08-15 | 1962-12-18 | Fmc Corp | N-aminoazetidine and preparation thereof |
| CA933923A (en) * | 1969-12-19 | 1973-09-18 | Eichenberger Kurt | Process for the manufacture of new thiopyranes |
| GB1570494A (en) * | 1975-11-28 | 1980-07-02 | Ici Ltd | Thienopyrimidine derivatives and their use as pesticides |
| DE2925175A1 (de) * | 1979-06-22 | 1981-01-08 | Basf Ag | Verfahren zur herstellung von isatosaeureanhydriden |
| IT1203323B (it) * | 1987-02-02 | 1989-02-15 | Hoechst Italia Spa | Additivo fotoattivatore per composizioni polimeriche costituito dal sale metallico di una cera ossidata |
| US5236917A (en) * | 1989-05-04 | 1993-08-17 | Sterling Winthrop Inc. | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
| DE4008726A1 (de) | 1990-03-19 | 1991-09-26 | Basf Ag | Thieno(2,3-d)pyrimidinderivate |
| US5143919A (en) * | 1990-08-17 | 1992-09-01 | Takeda Chemical Industries, Ltd. | Thienopyridine derivatives and their pharmaceutical use |
| JP3086295B2 (ja) * | 1990-08-17 | 2000-09-11 | 武田薬品工業株式会社 | チエノピリジン誘導体、その製造法およびacat阻害剤 |
| US5219864A (en) | 1991-03-12 | 1993-06-15 | Kyowa Hakko Kogyo Co., Ltd. | Thienopyridine derivatives |
| US5155115A (en) * | 1991-03-12 | 1992-10-13 | Kyowa Hakko Kogyo Co., Ltd. | Thienopyridine derivatives |
| US5227387A (en) * | 1991-09-03 | 1993-07-13 | Dowelanco | Quinoline nematicidal method |
| DE4138820A1 (de) * | 1991-11-26 | 1993-05-27 | Basf Ag | Chinolin-3-carbonsaeureamide, deren herstellung und verwendung |
| DE4208254A1 (de) * | 1992-03-14 | 1993-09-16 | Hoechst Ag | Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid |
| DE4227747A1 (de) * | 1992-08-21 | 1994-02-24 | Basf Ag | Heteroaromatisch kondensierte Hydroxypyridoncarbonsäureamide, deren Herstellung und Verwendung |
| US5409948A (en) | 1992-11-23 | 1995-04-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating cognitive disorders with phenserine |
| JPH06239858A (ja) * | 1993-02-16 | 1994-08-30 | Otsuka Pharmaceut Co Ltd | 末梢血管拡張剤 |
| GB9306460D0 (en) | 1993-03-29 | 1993-05-19 | Smithkline Beecham Plc | Novel compounds |
| GB9311562D0 (en) * | 1993-06-04 | 1993-07-21 | Fujisawa Pharmaceutical Co | Heterocyclic derivatives |
| TW449600B (en) * | 1994-04-19 | 2001-08-11 | Takeda Chemical Industries Ltd | Condensed-ring thiophene derivatives, their production and use |
| JP3829879B2 (ja) | 1994-05-18 | 2006-10-04 | 大正製薬株式会社 | キノリンカルボン酸誘導体 |
| GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
| DE19636769A1 (de) * | 1996-09-10 | 1998-03-12 | Basf Ag | 3-Substituierte Pyrido [4',3':4,5]thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung |
| DE19724980A1 (de) * | 1997-06-13 | 1998-12-17 | Basf Ag | 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung |
| JPH11130777A (ja) | 1997-08-13 | 1999-05-18 | Takeda Chem Ind Ltd | チエノピリジン誘導体、その中間体およびそれらの製造法 |
| ATE404539T1 (de) * | 1997-10-02 | 2008-08-15 | Eisai R&D Man Co Ltd | Kondensierte pyridinderivate |
| WO1999043681A1 (en) * | 1998-02-26 | 1999-09-02 | Neurogen Corporation | 4-(4-piperidylmethylamino) substituted heteroaryl fused pyridines: gaba brain receptor ligands |
| DE19815026A1 (de) * | 1998-04-03 | 1999-10-07 | Hoechst Schering Agrevo Gmbh | Substituierte Piperidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide |
| YU76100A (sh) | 1998-06-02 | 2003-12-31 | Osi Pharmaceuticals Inc. | Pirolo(2,3-d) pirimidin preparati i njihova primena |
| US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| EP1173168A2 (en) | 1999-04-28 | 2002-01-23 | Respiratorius AB | Compound for use as a medicament for treatment of disorders involving bronchocontraction |
| SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| AU763033B2 (en) | 1999-10-01 | 2003-07-10 | Japan Energy Corporation | Novel quinazoline derivatives |
| EP1270568A1 (en) | 2001-06-19 | 2003-01-02 | Biofrontera Pharmaceuticals AG | 1-methyl-4-(3-ethoxy-9h-thioxanthene-ylidene)-piperidine and its use as 5-HT2B and/or H1 antagonist |
| WO2003020728A1 (en) * | 2001-08-30 | 2003-03-13 | Pharmacia & Upjohn Company | 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS |
| MXPA03000145A (es) * | 2002-01-07 | 2003-07-15 | Pfizer | Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4. |
| WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| US20040138238A1 (en) * | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| WO2004030629A2 (en) | 2002-10-01 | 2004-04-15 | Predix Pharmaceuticals | Novel neurokinin antagonists and methods of use thereof |
| US20040097492A1 (en) * | 2002-11-01 | 2004-05-20 | Pratt John K | Anti-infective agents |
| US7153858B2 (en) * | 2003-01-31 | 2006-12-26 | Epix Delaware, Inc. | Arylpiperazinyl compounds |
| US20050222175A1 (en) * | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US7612078B2 (en) * | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| JP4677518B2 (ja) * | 2003-03-31 | 2011-04-27 | エピックス デラウェア, インコーポレイテッド | 新規ピペリジニルアミノ−チエノ[2,3−d]ピリミジン化合物 |
| US7119205B2 (en) * | 2003-05-16 | 2006-10-10 | Abbott Laboratories | Thienopyridones as AMPK activators for the treatment of diabetes and obesity |
| AU2004262897B9 (en) * | 2003-07-25 | 2009-12-17 | F. Hoffmann-La Roche Ag | Combination of mGluR2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders |
| GB0322140D0 (en) * | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
| EP2338490A3 (en) * | 2003-11-03 | 2012-06-06 | Probiodrug AG | Combinations useful for the treatment of neuronal disorders |
| US7488736B2 (en) | 2004-05-17 | 2009-02-10 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| US20060084806A1 (en) * | 2004-07-21 | 2006-04-20 | Ramasubramanian Sridharan | Processes for the preparation of imidazo[1,2-a] pyridine derivatives |
| US7576211B2 (en) * | 2004-09-30 | 2009-08-18 | Epix Delaware, Inc. | Synthesis of thienopyridinone compounds and related intermediates |
| US7407966B2 (en) * | 2004-10-07 | 2008-08-05 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| US7598265B2 (en) | 2004-09-30 | 2009-10-06 | Epix Delaware, Inc. | Compositions and methods for treating CNS disorders |
| WO2006081332A1 (en) * | 2005-01-25 | 2006-08-03 | Epix Delaware, Inc. | Substituted arylamine compounds and their use as 5-ht6 modulators |
| EP1965807A4 (en) * | 2005-11-23 | 2010-10-27 | Epix Delaware Inc | S1P RECEPTOR MODULATING COMPOUNDS AND THEIR USE |
| AR061637A1 (es) | 2006-06-26 | 2008-09-10 | Epix Delaware Inc | Composiciones y metodos de tratamiento de trastornos del snc |
| US20100184749A1 (en) | 2006-10-12 | 2010-07-22 | EPIX Delaware ,Inc. | Benzothiadiazine compounds and their use |
| AR064245A1 (es) | 2006-11-17 | 2009-03-25 | Epix Delaware Inc | Analogos de adenosina y su uso |
-
2004
- 2004-09-30 US US10/955,434 patent/US7488736B2/en not_active Expired - Lifetime
-
2005
- 2005-05-16 WO PCT/US2005/017121 patent/WO2005121151A2/en not_active Ceased
- 2005-05-16 CA CA2567268A patent/CA2567268C/en not_active Expired - Lifetime
- 2005-05-16 BR BRPI0510022-4A patent/BRPI0510022A/pt not_active Application Discontinuation
- 2005-05-16 RU RU2006144867/04A patent/RU2006144867A/ru not_active Application Discontinuation
- 2005-05-16 JP JP2007527345A patent/JP4897683B2/ja not_active Expired - Fee Related
- 2005-05-16 AU AU2005252632A patent/AU2005252632B2/en not_active Ceased
- 2005-05-16 EP EP05779361A patent/EP1746994A4/en not_active Withdrawn
-
2006
- 2006-11-01 IL IL178996A patent/IL178996A0/en unknown
- 2006-11-13 MA MA29451A patent/MA28582B1/fr unknown
- 2006-11-15 KR KR1020067023904A patent/KR101216296B1/ko not_active Expired - Fee Related
- 2006-12-15 NO NO20065814A patent/NO20065814L/no not_active Application Discontinuation
-
2008
- 2008-12-24 US US12/343,818 patent/US7982040B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2567268A1 (en) | 2005-12-22 |
| WO2005121151A2 (en) | 2005-12-22 |
| US20050256153A1 (en) | 2005-11-17 |
| IL178996A0 (en) | 2007-03-08 |
| JP2007538084A (ja) | 2007-12-27 |
| KR101216296B1 (ko) | 2012-12-28 |
| CA2567268C (en) | 2013-07-09 |
| BRPI0510022A (pt) | 2007-09-25 |
| US20090163537A1 (en) | 2009-06-25 |
| US7982040B2 (en) | 2011-07-19 |
| AU2005252632B2 (en) | 2012-03-01 |
| RU2006144867A (ru) | 2008-06-27 |
| WO2005121151A3 (en) | 2006-05-18 |
| US7488736B2 (en) | 2009-02-10 |
| MA28582B1 (fr) | 2007-05-02 |
| KR20070047237A (ko) | 2007-05-04 |
| EP1746994A2 (en) | 2007-01-31 |
| AU2005252632A1 (en) | 2005-12-22 |
| EP1746994A4 (en) | 2008-01-23 |
| JP4897683B2 (ja) | 2012-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20065814L (no) | Thiendopyridinon forbindelser og fremgangsmater for behandling | |
| WO2005040135A1 (ja) | 抗ストレス薬およびその医薬用途 | |
| NO20072348L (no) | Thienopyridinone sammensetninger og fremgangsmate for behandling | |
| JPH07149762A (ja) | ピペリジン類およびピペラジン類 | |
| WO2004069794A3 (en) | New arylpiperazinyl compounds | |
| JPWO2005047286A1 (ja) | スピロ複素環化合物 | |
| TW200628472A (en) | Piperidinylamino-thieno (2,3-d) pyrimidine compounds | |
| ATE402935T1 (de) | Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen | |
| ATE511511T1 (de) | Neue piperidinylaminothienoä2,3-dü pyrimidinverbindungen | |
| JP2005535659A (ja) | 嘔吐、抑鬱、不安および咳の処置のためのニューロキニン−1(nk−1)アンタゴニストとしての1−アミド−4−フェニル−4−ベンジルオキシメチル−ピペリジン誘導体および関連化合物 | |
| CN101903340A (zh) | 取代的n-苯基联吡咯烷羧酰胺及其治疗用途 | |
| JP2003524571A (ja) | インドール−及び2,3−ジヒドロインドール誘導体、その製造方法及びその使用方法 | |
| JP6950534B2 (ja) | テトラヒドロナフタレン誘導体 | |
| CA2559530C (en) | Novel benzyl(idene)-lactam derivatives | |
| ATE449092T1 (de) | Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors | |
| JP6943239B2 (ja) | Kcnq2〜5チャネル活性化剤 | |
| JP4865710B2 (ja) | 情動障害、疼痛、adhdおよび腹圧性尿失禁の治療に使用するための2−(1h−インドリルスルファニル)−アリールアミン誘導体 | |
| JP4216072B2 (ja) | ドーパミンd2受容体及びセロトニン再取り込み部位に対する高い親和性を有する8−{4−[3−(5−フルオロー1h−インドール−3−イル)−プロピル]−ピペラジン−1−イル}−2−メチル−4h−ベンゾ[1,4]オキサジン−3−オンメシラート | |
| PH12012502348A1 (en) | Novel spiroheterocyclic compounds as mglu5 antagonists | |
| Mésangeau et al. | Preparation and pharmacological evaluation of a novel series of 2-(phenylthio) benzo [b] thiophenes as selective MT2 receptor ligands | |
| WO2007069671A1 (ja) | 二環式複素環化合物 | |
| CN101501008B (zh) | 芳基哌嗪衍生物及其用途 | |
| CN1304409A (zh) | 用于治疗抑郁症的吲哚-3-基-环己胺衍生物(5-ht1受体拮抗剂) | |
| WO2006024955A1 (en) | Azabicyclic amine histamine-3 receptor antagonists | |
| UA87845C2 (ru) | Производные тиенопиридинона и способ лечения расстройств нервной системы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |